Alloy Therapeutics Raises $40 Million in Series E Funding
Alloy Therapeutics, a Boston-based biotechnology company, has announced the successful closure of a $40 million Series E funding round. The company is known for democratizing access to antibody and biologics discovery technology, which is pivotal in advancing drug discovery in antibodies and T cell receptors (TCRs).
Investment Details
The Series E round was led by 8VC, JIC Venture Growth Investments, and Echo Capital. Other notable participants included Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, and Ulysses Diversified Holdings.
Company Leadership
Founded and led by CEO Errik Anderson, Alloy Therapeutics is positioned as a significant player in the biotechnology sector. Anderson is joined by Kelsey Smith, who serves as the Associate Director, Office of the CEO, and Richard Shimkets, who is the CEO of the Antibody-POWERED division within the company.
Strategic Use of Funds
While the company did not specify the exact allocation of the newly raised funds, the investment will likely support Alloy Therapeutics in expanding its technology platforms and enhancing its service offerings in the drug discovery space.
Conclusion
This latest funding round underscores Alloy Therapeutics’ commitment to being a major contributor to the biotech infrastructure landscape, as it continues to innovate and provide access to critical drug discovery technologies. With this new capital, Alloy is well-positioned to further its mission of advancing drug discovery through its comprehensive technology ecosystem.